TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Death, stroke, or AKI by 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: 10-year ASCVD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QoL value for physical and social function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: faecal wet weight excretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Grade 2 or worse hand-foot syndrome (HFS)
Endpoint domain: Adverse events/effects
Primary endpoint: improvements in non-specific chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of beta(3)-adrenoceptor in adipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: long-term overall survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: family burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Decrease of blood uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relaxed tolerance to Gz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nightly compliance with CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RR variability measures (NN50, pNN50, low frequency power)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between patient-reported and physician-reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Agreement between patient-reported and physician-reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intact FGF23 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for surgical technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impaired LV relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of psychosis emergence or confusion
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of morphological variations of the endothelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAI GMTs and seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: additional biliary events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: recurrent cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: additional cholecystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Energy expenditure upon mild cold exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rapid clinical improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quit smoking rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: use of a second injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in height and length of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall appearance criteria improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of END
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of deep-vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Remaining deep sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of swelling of perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perineal swelling remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year locoregional control (LRC)
Endpoint domain: Mortality/survival
Primary endpoint: 3-year completion rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of pelvic inflammatory disease
Endpoint domain: Adverse events/effects
Primary endpoint: complete/partial expulsion rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative IV-PCA dose (mg of hydromorphone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days longer to heal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antral manometric motility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Amplitude of antral contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in sexual health risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of mouthpiece ventilation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADL scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient adherence to program recommendations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: RV size and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurohumoral activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FGF‐23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 m sprint speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag time (Tlag)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas under the plasma concentration–time curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral burden of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S. mansoni infection not detectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: percentage of spelling-disabled children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of typical antipsychotic agents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in symptoms (20% or more)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of tender or swollen joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Driving impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vision disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response of the antioxidant system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days alive and out of the hospital within 30 days of surgery
Endpoint domain: Mortality/survival
Primary endpoint: Attendance to screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of cancers and adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: improvement in patient and family functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Neck Disability Index improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance or improvement in neurological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative rates for surgery at the index level
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived acceptability of industry-sponsored gifts
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Grade 3/4 toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for Gengraf over Neoral
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with capsule characteristics (odor, swallowing, taste)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean AUC > 140 mg/dL/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean interstitial glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic variability indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in glycated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean nocturnal frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average plasma all‐E‐lutein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose‐normalized lutein bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity rates of the CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity rates of the CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety levels measured by Hospital Anxiety and Depression Scale-A
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean glucose measure-to-measure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Oxycodone DETERx®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Oxycodone DETERx®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time to unassisted walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor uptake of FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-extraction ridge contour loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual attention/spatial ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal thyroid function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Tibial slope accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: risk of symptomatic thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: risk of pneumothorax requiring chest-tube insertion
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour urinary phenylacetylglutamine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morning spot urine phenylacetylglutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori infection eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects attributable to trial medication
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactate responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in [CK] at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: testosterone levels post SS and TRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cerebral oxygen supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygen extraction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Recognition of findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy (median distance from target)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Harvest time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: survival of the graft
Endpoint domain: Mortality/survival
Primary endpoint: Health rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pain-free grip force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treadmill time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative lung dose of salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correct extraction of systolic and diastolic blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correct extraction of laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure rates at TOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS-BMD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine massage compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement of micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antegrade ejaculation preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sexual function satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: confirmed overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: malondialdehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: paraoxonase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total antioxidative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total oxidative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Content of TNF‐α, IL‐6, and IL‐8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Content of T‐lymphocyte subsets and NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reductions in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in fasting blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-yr increases in spine and hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression relapse/recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of wearing off, dyskinesias, or on‐off motor fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in total UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with retention of mandibular dentures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Health Related Quality of Life (OHRQoL) for Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RT(G) values estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of NovoTwist needle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Confidence in needle attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: closed infarct-related artery or death/myocardial infarction before angiography
Endpoint domain: Mortality/survival
Primary endpoint: cardiovascular death, myocardial infarction, or urgent revascularization through 30 days
Endpoint domain: Mortality/survival
Primary endpoint: BMD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Chronic pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gastrointestinal adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Progression to advanced AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 36-month survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Connectivity between the insula and DMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fraction Shortening (FS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: N-terminal pro-B-type natriuretic peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exposure of collagen fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of flatus production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum knee joint torque during standing-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: well-being affected by agricultural stressors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Error-free care rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Borg score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cough incidence
Endpoint domain: Adverse events/effects
Primary endpoint: RMQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Knowledge posttest score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on surgical assessment tools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of severe CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of silent CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major clinical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of referring PPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean referral rate per PP-year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Smear-positive PTB case-finding rate per PP-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mucosal healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemorrhagic stroke incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Plasma level of brain natriuretic peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalization of alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Decrease in liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean ED50 (microgram/kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal depression percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month adherence overall
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 6-month adherence overall
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: SF‐36 Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF‐36 Vitality
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: LDL cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes